What is DAXXIFY™ and how is it different?
DAXXIFY™–the only long-lasting, peptide-powered frown line treatment. We’re one of the first exclusive providers to offer this innovative treatment. or learn more at DAXXIFY.com
DAXXIFY™ is FDA approved to help smooth moderate to severe lines between the brows. It is the only long-lasting frown line treatment powered by a peptide with results that last on average 6 months and up to 9 months for some.*
Conventional injectables last 3 – 4 months and require up to 4 treatments a year to maintain results. Nearly 90% of patients say they wish results lasted longer.
With DAXXIFY™ you can keep your frown lines smoother for a full year with as few as 2 treatments.*
*At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.
Why are peptides important?
All frown line treatments require a special ingredient to stabilize botulinum toxin A, the protein responsible for helping smooth moderate to severe frown lines. For instance, BOTOX® Cosmetic uses human serum albumin (HSA), a blood product, as its stabilizer. Dysport®, another frown line treatment, uses HSA as a stabilizer and cow’s milk protein as a protectant.
DAXXIFY™ is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts.
Is DAXXIFY™ well studied?
DAXXIFY™ was studied in the largest-ever clinical study conducted for a frown line treatment and included more than 2,400 people across different ages and skin types.
• There were no serious treatment-related side effects in clinical trials for
DAXXIFY™
• The active ingredient in DAXXIFY™ is botulinum toxin type A, an ingredient that
has been used in frown line treatments for more than 20 years
• 96% of people treated with DAXXIFY™ were satisfied with their results†
†96% of patients reported they were satisfied on a 7-point scale when evaluated at 4 weeks in clinical
studies.